Learning objectives
After this module you should be able to:
- Set weight-loss targets linked to liver histology, and explain where guidelines differ.
- Write a practical diet and activity plan adapted to Gulf eating habits.
- Assess and advise on alcohol and smoking, including MetALD.
- Recognise when to add obesity medicines or metabolic surgery, and adapt advice in cirrhosis, sarcopenia and Ramadan.
Boxed recommendations are paraphrased from the EASL–EASD–EASO 2024 guideline, with its grades: evidence level from 1 (strongest) to 5; recommendation strong, weak or open; consensus is the panel's agreement (strong means at least 95%).
1Why lifestyle is the foundation
Metabolic dysfunction-associated steatotic liver disease (MASLD) grows out of excess energy intake, poor diet quality and inactivity, and type 2 diabetes and obesity are its strongest drivers [1]. Lifestyle change treats these causes directly. It is therefore the first step at every stage, from simple steatosis to compensated cirrhosis, and it continues when drugs or surgery are added.
Weight loss achieved through diet and behavioural therapy should be advised for adults with MASLD, because it improves liver injury on histology and on non-invasive tests. [1]
Cardiovascular disease and cancer are the main causes of death in MASLD [2], and the same diet and activity changes lower cardiovascular risk [1,3]. The weak point is evidence on hard liver outcomes: lifestyle trials have lasted 2–24 months, and data on death, decompensation and liver cancer remain sparse [1].
2Weight-loss targets
In overweight adults with MASLD, aim for sustained weight loss of at least 5% to reduce liver fat, 7–10% to reduce inflammation, and at least 10% to improve fibrosis. [1]
These thresholds come largely from one prospective study of 293 patients with biopsy-proven steatohepatitis who were coached in lifestyle change for 52 weeks. Only 30% lost 5% or more of their weight. Among those who lost at least 10%, steatohepatitis resolved in 90% and fibrosis regressed in 45%; the greater the weight loss, the greater the histological gain [4].
| Guidance | Liver fat | Inflammation (MASH) | Fibrosis |
|---|---|---|---|
| EASL–EASD–EASO 2024 | ≥5% | 7–10% | ≥10% |
| AASLD 2023 | 3–5% | >10% | >10% |
| Global consensus 2025 | 5% (3–5% if lean) | 7–10% | 10% |
| Saudi consensus 2026 | At least 5%, ideally more than 10% (single target) | – | – |
AASLD sets a lower bar for steatosis (3–5%) but asks for more than 10% for both steatohepatitis and fibrosis; EASL and the global consensus place inflammation at 7–10% [1,3,5]. In normal-weight MASLD, EASL still advises diet and exercise to reduce liver fat (LoE 3, strong recommendation), and the global consensus suggests a 3–5% target, although no study has shown an effect on fibrosis or outcomes in this group [1,5].
Weight regain is the rule, not the exception. At most 1 in 10 patients achieve effective weight loss at one year despite structured programmes, and fewer than half of these keep it off at five years [3]. In longer diet trials, weight loss peaks at about six months and settles at a net loss of about 5% by 12–24 months [1].
3Diet quality and the calorie deficit
Advise a better-quality diet along the lines of the Mediterranean pattern, fewer ultra-processed foods rich in sugar and saturated fat, and no sugar-sweetened drinks. [1]
For patients with overweight, the core is a calorie deficit. Low-carbohydrate and low-fat hypocaloric diets reduce liver fat to a similar degree, so the best diet is the one the patient can keep [1,3]. The Mediterranean pattern (olive oil, vegetables, whole fruit, legumes, nuts, whole grains, fish) has added cardiometabolic value and is easier to sustain. Evidence is insufficient for very-low-carbohydrate ketogenic diets, and time-restricted eating has not clearly beaten simple calorie restriction for liver fat [1].
Fructose intake is linked to MASLD and, in AASLD's reading, to steatohepatitis and advanced fibrosis independent of calories [3]. Sugar-sweetened drinks are linked to liver fat and to new MASLD in a dose-dependent way [1]. Nutraceuticals and supplements cannot be recommended (LoE 2, open recommendation) [1].
Coffee is where guidelines part ways. AASLD states that 3 or more cups a day, caffeinated or not, could be recommended if there is no contraindication [3]. EASL accepts the observational link with less fibrosis and fewer liver deaths (LoE 4) but draws no firm conclusion, because trials are few and negative or inconclusive [1]. A reasonable line is not to discourage coffee, without sugar, in patients who already drink it.
| Habit | Why it matters | Practical swap |
|---|---|---|
| Soft drinks, energy drinks, packaged juices | Sugar-sweetened drinks and added fructose | Water, sparkling water, unsweetened drinks; whole fruit instead of juice |
| Sweet tea through the day | Repeated added sugar | Reduce sugar step by step to none; fewer cups |
| Large rice portions (kabsa, mandi) twice a day | Refined starch and excess energy | Smaller rice portion, half the plate vegetables, add legumes; brown rice or whole grains |
| Dates as frequent snacks | Energy-dense natural sugar | Count dates as a fruit portion and keep to a few; pair with nuts or laban |
| Fried snacks, fast food, processed meat | Ultra-processed, saturated fat, processed red meat | Grilled fish or poultry, olive oil, home-cooked meals |
| Daily sweets and pastries | Added sugar and refined flour | Keep for occasions, in small portions |
4Physical activity and resistance training
Prescribe physical activity tailored to the patient's preference and ability, ideally more than 150 minutes a week of moderate or 75 minutes of vigorous activity, to reduce steatosis. [1]
Exercise reduces liver fat even without weight loss. Aerobic, resistance and high-intensity interval training all work; EASL prefers aerobic plus resistance training [1]. Evidence for an effect on histology and fibrosis is weaker than for steatosis (LoE 5), but exercise improves fitness, visceral fat and muscle mass, even in advanced disease [1].
The global consensus gives a wider range: 150–300 minutes of moderate or 75–150 minutes of vigorous activity a week, with less sitting time [5]. In practice, start from what the patient does now, add brisk walking in cool hours or indoors (malls, home), and add simple resistance work with body weight or bands.
5Alcohol, MetALD and smoking
Record the amount, pattern and history of alcohol use in every person with steatotic liver disease. [1]
Discourage alcohol in steatotic liver disease, especially when intake is moderate or high. [1]
People with advanced fibrosis or cirrhosis should stop all alcohol, completely and for good. [1]
Alcohol and metabolic risk factors act together, and the combined effect can be greater than the sum [1]. Recent data no longer support a protective effect of light drinking, particularly in people with cardiometabolic risk factors [1]. Ask every patient, including where alcohol use is uncommon or under-reported; AUDIT-C takes three questions [1].
| Category | Women (g/day) | Men (g/day) | Advice |
|---|---|---|---|
| MASLD | <20 | <30 | Discourage alcohol |
| MetALD | 20–50 | 30–60 | Discourage firmly; aim for abstinence |
| Alcohol-related liver disease | >50 | >60 | Abstinence; treat alcohol use disorder |
| Any category with advanced fibrosis or cirrhosis | – | – | No alcohol at all, permanently |
The threshold for complete abstinence differs. EASL sets it at advanced fibrosis or cirrhosis, whereas AASLD asks patients with fibrosis stage F2 or more to abstain [1,3]. The global consensus advises minimising alcohol, especially in advanced disease [5]. AASLD also uses slightly different cut-offs for moderate drinking (21–39 g/day in women, 31–59 g/day in men) [3].
Smoking adds liver risk. In a meta-analysis of 81 studies, the odds of liver cancer were 1.55 times higher in current smokers and 1.39 times higher in former smokers [1]. Advise stopping all tobacco products and offer cessation support; the global consensus lists smoking cessation as part of the lifestyle plan [5].
6Behaviour change in the clinic
Advice alone rarely changes weight. EASL describes behavioural therapy as self-monitoring, building the patient's confidence and motivation, setting realistic goals that are negotiated rather than imposed, and working through barriers [1]. AASLD adds that a team approach, with dietitians, behavioural specialists and family involvement, does better than physician counselling alone [3].
- Ask about a usual day's food and drink, activity, alcohol and smoking.
- Explain: link the plan to a number the patient can follow, such as weight, waist or a repeat FIB-4.
- Agree: choose one or two changes the patient chooses, for example stopping soft drinks and walking after the evening meal.
- Record: ask the patient to log weight, steps or meals between visits.
- Review: weigh at each visit, praise progress, solve the next barrier, and refer to a dietitian when available.
7When lifestyle is not enough
GLP-1 receptor agonists are safe in MASH, including compensated cirrhosis, and should be used for their licensed indications of type 2 diabetes and obesity, because they improve cardiometabolic outcomes. [1]
Obesity medicines make a 10% target reachable: semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% in STEP 1 [6]. In ESSENCE, 72 weeks of semaglutide 2.4 mg resolved MASH in 62.9% versus 34.3% on placebo and improved fibrosis in 36.8% versus 22.4%, in patients with F2–F3 fibrosis [6]. EASL 2024, written before ESSENCE, did not endorse GLP-1 receptor agonists as MASH-targeted therapy, and does not recommend non-incretin weight-loss drugs for that purpose [1]. Approval differs by country: check local (SFDA) approval and the label before prescribing. Lifestyle change continues alongside any drug [6].
In adults with non-cirrhotic MASLD who meet the indications for metabolic surgery, bariatric surgery should be considered for its lasting liver benefit, diabetes remission and cardiometabolic gains. [1]
The randomised BRAVES trial assigned 288 adults with biopsy-proven steatohepatitis to lifestyle plus best medical care, Roux-en-Y gastric bypass or sleeve gastrectomy. At one year, steatohepatitis resolved without worsening fibrosis in 56% after bypass and 57% after sleeve gastrectomy, against 16% with lifestyle care; 6% of surgical patients had a severe adverse event, and none died [7]. In a French cohort of 180 patients, steatohepatitis had resolved in 84% at five years and fibrosis had decreased in 70% [8].
Indications follow body mass index and comorbidity, and surgical societies updated them in 2022 [9]. EASL summarises them as BMI 40 kg/m² or more; 35–40 with comorbidities; or 30–35 with poorly controlled type 2 diabetes or hypertension despite optimal medical therapy, with lower thresholds in Asian populations [1].
In compensated advanced chronic liver disease or compensated cirrhosis, bariatric surgery can be considered only after careful review of the indication, type of operation and portal hypertension by an experienced multidisciplinary team. [1]
Cirrhosis changes the balance. People with decompensated cirrhosis are about ten times more likely to die after bariatric surgery than those whose cirrhosis is compensated; EASL avoids surgery with clinically significant portal hypertension except in highly selected cases in expert centres [1]. EASL, AASLD and the Saudi consensus all treat decompensated cirrhosis as a contraindication unless surgery is part of liver transplant planning [1,3,2]. Endoscopic bariatric procedures are not yet recommended as MASH treatment [1,2].
8Muscle, cirrhosis and older adults
In sarcopenia, sarcopenic obesity or decompensated cirrhosis, provide a high-protein diet and a late-evening snack. [1]
In compensated cirrhosis with obesity, moderate weight loss can be suggested, with high protein intake and physical activity to protect muscle. [1]
Sarcopenia affects 50–60% of people with cirrhosis awaiting transplantation, and sarcopenic obesity, low muscle with excess fat, is found in 20–35% of people with cirrhosis around transplantation [1]. In non-obese patients with cirrhosis, most nutrition plans supply at least 35 kcal/kg/day and 1.2–1.5 g/kg/day of protein. For obese patients with compensated cirrhosis, the EASL nutrition guideline cited in 2024 suggests 5–10% weight loss on a moderately hypocaloric diet (500–800 kcal/day below needs) while keeping protein above 1.5 g/kg of ideal body weight [1]. Avoid long gaps without food: eat every 4–6 hours and add a late-evening snack [1].
Muscle loss on GLP-1 therapy is more marked in older people and in those with sarcopenia [6]. In older patients, put strength and protein first and set modest weight goals.
9Our region: Saudi consensus and Ramadan
The Saudi 2026 consensus recommends lifestyle change for patients with excess body fat: structured, individualised exercise, a healthy diet with less saturated fat and starch, and weight loss of at least 5%, ideally more than 10%, together with control of metabolic risk factors (high level of evidence). It also advises diet and exercise for normal-weight MASLD (moderate evidence) [2]. It sets bariatric thresholds for Saudi patients at BMI 35–39.99 kg/m² with comorbidities and 40 or more without, and calls for a multidisciplinary review before surgery in well-compensated cirrhosis [2].
A 2025 meta-analysis of Ramadan fasting pooled eight small studies (603 people with metabolic dysfunction-associated fatty liver disease), most at serious risk of bias. It found slightly more weight loss in those who fasted (about 1.4 kg) than in non-fasters, while changes in ALT and AST were similar in both groups [10]. The evidence is too weak to present fasting as a liver treatment. A recent Saudi review calls for risk-stratified, culturally sensitive advice across the spectrum from MASLD to cirrhosis and transplantation [11].
- Plan before Ramadan: review diabetes medicines and doses with the patient's diabetes team, especially insulin and sulfonylureas.
- Use the month: suhoor and iftar are a chance to cut sugary drinks, fried foods and sweets.
- Cirrhosis needs an individual decision: EASL advises short gaps between meals and a late-evening snack, which a long daytime fast does not allow [1].
10Clinical case
A 46-year-old man with diabetes and a sweet tooth
- Presentation
- Office worker in Jeddah with type 2 diabetes for three years, on metformin; HbA1c 7.4%. Weight 98 kg, height 1.70 m: BMI = 98 ÷ (1.70 × 1.70) = 98 ÷ 2.89 = 33.9 kg/m². Ultrasound shows steatosis. AST 38 U/L, ALT 52 U/L, platelets 245 ×10⁹/L. He drinks three to four cans of soft drink and several cups of sweet tea a day, eats rice at lunch and dinner, and snacks on dates. He is inactive, smokes 10 cigarettes a day, and drinks no alcohol (AUDIT-C 0).
- Risk assessment
- FIB-4 = (46 × 38) ÷ (245 × √52) = 1,748 ÷ (245 × 7.21) = 1,748 ÷ 1,767 = 0.99. This is below 1.3, so advanced fibrosis is unlikely. The main task is lifestyle and cardiometabolic care in primary care.
- The prescription
- First target 5%: 98 × 0.05 = 4.9 kg, to about 93 kg. Longer-term target 10%: 9.8 kg, to about 88 kg. He chooses two changes: water instead of soft drinks, and tea with less sugar each week until none. Rice portion halved, with vegetables and legumes; dates counted as fruit. Walking after the evening meal, building up to more than 150 minutes a week, plus body-weight exercises. Smoking cessation clinic referral. He plans to fast in Ramadan, so his diabetes plan is reviewed beforehand.
- Six months later
- Weight 91.0 kg: loss = 7.0 kg, and 7.0 ÷ 98 = 7.1%. BMI = 91 ÷ 2.89 = 31.5 kg/m². ALT has fallen to 34 U/L. He has stopped soft drinks and cut down to 4 cigarettes a day. He has passed the 5% target and is within the 7–10% band; the plan continues toward 10%. If weight loss stalls, a GLP-1 receptor agonist for his diabetes and obesity is a reasonable next step, after checking local SFDA approval and the label.
- Teaching points
- Two changes chosen by the patient beat a long list of rules, and targets in kilograms are easier to follow than percentages. A low FIB-4 decides where care happens, not whether lifestyle change is needed.
11Test yourself
Choose an answer to see the explanation. Nothing is recorded.
1. According to EASL–EASD–EASO 2024, what sustained weight loss is needed to improve fibrosis?
EASL links at least 5% to less liver fat, 7–10% to less inflammation and at least 10% to fibrosis improvement.
2. A man with type 2 diabetes and steatosis drinks about 40 g of alcohol a day. How is he classified?
In men, 30–60 g/day with a cardiometabolic risk factor defines MetALD. He should be firmly advised to stop.
3. Which activity target does EASL recommend for adults with MASLD?
EASL recommends more than 150 minutes of moderate or 75 minutes of vigorous activity a week, tailored to the patient; exercise lowers liver fat even without weight loss.
4. A patient with decompensated MASH cirrhosis and BMI 41 asks about sleeve gastrectomy. What is the best answer?
Decompensated cirrhosis carries about a 10-fold higher surgical mortality; EASL, AASLD and the Saudi consensus all advise against surgery outside transplant planning.
5. A 68-year-old woman on semaglutide has lost 12% of her weight. What should you add?
About 39% of weight lost on semaglutide is lean mass, more so in older adults; AASLD advises resistance exercise and adequate protein.
12Key messages
- Lifestyle change is the first treatment at every stage of MASLD and continues alongside drugs or surgery.
- Targets (EASL): at least 5% weight loss for fat, 7–10% for inflammation, at least 10% for fibrosis; plan for maintenance.
- Cut sugary drinks, added sugar, refined starch and ultra-processed food; move more than 150 minutes a week, with resistance work.
- Ask about alcohol and tobacco in everyone; no alcohol at all with advanced fibrosis or cirrhosis (AASLD: from F2).
- Add obesity medicines or metabolic surgery when lifestyle is not enough; in cirrhosis protect muscle and avoid surgery once decompensated.
References
- EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol 2024;81:492–542. doi:10.1016/j.jhep.2024.04.031
- Abaalkhail F, et al. MASLD management in Saudi Arabia: a modified Delphi-based adaptation of international standards. Saudi J Gastroenterol 2026;32(2):104–20. doi:10.4103/sjg.sjg_199_25
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of NAFLD. Hepatology 2023;77:1797–835. doi:10.1097/HEP.0000000000000323
- Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–78. doi:10.1053/j.gastro.2015.04.005
- Younossi ZM, et al. Global consensus recommendations for MASLD and MASH. Gastroenterology 2025;169(5):1017–32. doi:10.1053/j.gastro.2025.02.044
- Bansal MB, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology 2026;83(5):1326–40. doi:10.1097/HEP.0000000000001608
- Verrastro O, et al. Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in NASH (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023;401(10390):1786–97. doi:10.1016/S0140-6736(23)00634-7
- Lassailly G, et al. Bariatric surgery provides long-term resolution of NASH and regression of fibrosis. Gastroenterology 2020;159:1290–1301. doi:10.1053/j.gastro.2020.06.006
- Eisenberg D, et al. 2022 ASMBS and IFSO indications for metabolic and bariatric surgery. Surg Obes Relat Dis 2022;18:1345–56. doi:10.1016/j.soard.2022.08.013
- Kamrul-Hasan ABM, et al. Impacts of Ramadan fasting on metabolic and hepatic endpoints in individuals with metabolic dysfunction-associated fatty liver disease: a systematic review and meta-analysis. JGH Open 2025;9(8):e70264. doi:10.1002/jgh3.70264
- Khalifa R, et al. Intermittent fasting and liver disease: insights from the Ramadan model. Saudi J Gastroenterol 2026;32(2):93–103. doi:10.4103/sjg.sjg_120_25
How to cite this module
Desoky M. The lifestyle prescription. Metabolic Liver Academy, version 1.0. Updated 2026-10-03. Available from: https://drmahmouddesoky.github.io/metabolic-liver-academy/modules/lifestyle-prescription.html
For education only. This module summarises published evidence and guidelines; it does not replace clinical judgement, full guidelines or local drug labels. It is not accredited for CME credit. Disclaimer.